| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Vaccines | Infectious Diseases | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Vaccines | Infectious Diseases | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Vaccines | Infectious Diseases |
Recent Updates
Recently added Catalysts
Vaxcyte, Inc.$58.21
-1.84 (-3.08%)
D 36Pipeline Score Richly Valued Biotech · Clinical
Market Cap
6.83 B
EPS
-6.97
P/E Ratio
-
Value Trade
70.92 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
312.78 M
Operating CF
-280.63 M
Total Assets
3.35 B
Total Liabilities
352.29 M
Equity
3.00 B
D/E Ratio
12,345
-10.96 %
Week
-22.47 %
1 Month
-17.29 %
3 Month
-0.53 %
6 Month
134.97 %
5 Year
127.4 %
All Time
Cash Data
Cash Position
1.74 B
Monthly Burn
93.54 M
Runway
16.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
623.97 K
52 Week Range
29.08 - 65
% held by Insiders
2.39 %
% held by Institutions
111.57 %
Enterprise Value
5.21 B
Total Shares
144.45 M
Short %
13.77 %
Float Shares
126.82 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vaxcyte, Inc.
288Total events
7Upcoming
56Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 7
Q1 2027
T1Topline Readout
Complete booster data from VAX-31 infant Phase 2 study expected up to nine months after primary series data
Event history 281
Q2 2026
◆Topline Readoutof the low dose VAX-31Clinical Data
Topline safety, tolerability and immunogenicity data from primary three-dose immunization series of VAX-31 infant Phase 2 study expected
Infant pneumococcal diseasesource ↗
Jun 2, 2026
▲First Patient DosedVAX-A1Trial
First participant dosed in Phase 1 study of VAX-A1
Group A Streptococcussource ↗
Jun 2026
◆Trial InitiationVAX-A1Trial
Initiation of Phase 1 adult clinical study for VAX-A1 expected
Group A Strep diseasesource ↗
May 6, 2026
▲Enrollment Completeof the low dose VAX-31Trial
Enrollment completed for OPUS-1 Phase 3 trial
Invasive Pneumococcal Disease and Pneumoniasource ↗
May 6, 2026
●Manufacturing MilestoneCMC / Inspection
Completed construction of dedicated large-scale manufacturing facility with Lonza
Apr 14, 2026
◆Oral PresentationPresentation
Vaxcyte management to present at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Topline Readoutof the low dose VAX-31Clinical Data
Topline safety, tolerability and immunogenicity data from primary immunization series
invasive pneumococcal diseasesource ↗
Mar 23, 2026
▲Enrollment Completeof the low dose VAX-31Trial
Enrollment completed in OPUS-1 Phase 3 trial of VAX-31
Invasive Pneumococcal Disease and Pneumoniasource ↗
Mar 2026
▲Publicationof the low dose VAX-31Presentation
Positive VAX-31 Phase 1/2 adult data published in The Lancet Infectious Diseases
Invasive Pneumococcal Disease and Pneumoniasource ↗
Feb 24, 2026
Feb 12, 2026
◆Oral PresentationPresentation
Vaxcyte management to present at Guggenheim Emerging Outlook: Biotech Summit
Drug Pipeline Intelligence
D36
Pipeline Score $787M
Pipeline ValueRichly Valued
Valuation Signal5
Drugs Scored0.1x
rNPV / MCap Top 49%
Small Cap (rank 466 of 911)
Percentile RankVaxcyte, Inc. faces pipeline headwinds (36/100), with $1.2B risk-adjusted pipeline value, led by of the low dose VAX-31 in Pneumococcal Vaccines (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| of the low dose VAX-31 Monoclonal antibody | Pneumococcal Vaccines | Phase 2 | NCT06720038 | 53% | $363M | ACTIVE NOT_RECRUITING | 900 | VERY_FAST | B (75) | Dec 1, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VAX-24 Breakthrough | infant | Phase 2 | 2025-11-04 | VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed. Read More | Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study Read More | |
VAX-24 Breakthrough | infant | Phase 2 | 2025-11-04 | VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed. Read More | Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study Read More | |
VAX-24 Breakthrough | infant | Phase 2 | 2025-11-04 | VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed. Read More | Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PCVX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PCVX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PCVX▼ -3.1%today
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced its participation in upcoming investor conferences, including the Leerink Partners Therapeutics Forum and the BTIG Virtual Biotechnology Conference. The company will host one-on-one meetings to discuss its innovative vaccine pipeline, which includes candidates aimed at addressing invasive pneumococcal disease and Group A Strep. Vaxcyte's advancements in vaccine technology underscore its commitment to public health.
Read more →PCVXVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte has initiated a Phase 1 study for VAX-A1, a vaccine aimed at preventing diseases caused by Group A Streptococcus in healthy adults. The study will assess safety and tolerability, with initial data expected in late 2027. Group A Strep poses a significant public health threat, with no existing vaccine and rising infection rates.
Read more →PCVX▼ -9.8%on this news
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte, Inc. reported its first quarter 2026 financial results, highlighting the completion of enrollment in its OPUS Phase 3 trials for VAX-31, aimed at preventing invasive pneumococcal disease. The company anticipates topline data from OPUS-1 in Q4 2026 and results from OPUS-2 and OPUS-3 in H1 2027. Vaxcyte also plans to initiate a Phase 1 study for its VAX-A1 vaccine candidate in mid-2026, supported by a strong financial position.
Read more →PCVXVaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 14, 2026. The company's management will engage in a fireside chat, which will be accessible via a live webcast. Vaxcyte is known for its innovative vaccine development, including its leading candidates VAX-31 and VAX-24.
Read more →PCVXVaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte has completed enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a next-generation pneumococcal conjugate vaccine. The OPUS-1 trial will compare VAX-31's safety and immunogenicity against existing vaccines, while OPUS-2 will assess its administration alongside seasonal influenza vaccines. Results are anticipated in late 2026 and early 2027, respectively.
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte, Inc. reported its fourth quarter and full year 2025 financial results, highlighting progress in its VAX-31 Phase 3 clinical program for pneumococcal vaccines. The company has completed enrollment for its infant Phase 2 study and is advancing its early-stage pipeline with plans for a Phase 1 study of VAX-A1. Vaxcyte also announced strong financials, with $2.4 billion in cash and investments.
Read more →PCVXVaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte has initiated the OPUS-3 Phase 3 trial for its VAX-31 vaccine, targeting adults previously vaccinated with lower-valency pneumococcal vaccines. This trial aims to assess the safety, tolerability, and immunogenicity of VAX-31, which is designed to cover a wide range of pneumococcal diseases. The company expects to report topline data from this and other related trials by 2027.
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc. will report its fourth quarter and full year 2025 financial results on February 24, 2026. Following the report, the company will host a conference call and webcast to discuss the results and provide a business update. Vaxcyte is known for its innovative vaccine candidates, including VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease.
Read more →PCVXVaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte, Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. The management will engage in a fireside chat, which will be available via live webcast. Vaxcyte is known for its innovative vaccine candidates, including VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease.
Read more →PCVXVaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte, Inc. has successfully closed a public offering of 12,650,000 shares at $50.00 each, raising a total of $632.5 million. This includes the full exercise of an option by underwriters to purchase additional shares. The funds will support Vaxcyte's ongoing development of its vaccine candidates, including VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease.
Read more →PCVXVaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte, Inc. has announced a public offering of 11 million shares at $50 each, aiming to raise $550 million. The offering is set to close on February 2, 2026, pending customary conditions. Vaxcyte is focused on developing advanced vaccines, including candidates for pneumococcal disease and Group A Strep infections.
Read more →PCVXVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte, Inc. has commenced a public offering of $500 million in common stock and pre-funded warrants, with an option for underwriters to purchase an additional $75 million. The offering is contingent on market conditions and is part of the company's ongoing development of its vaccine candidates for bacterial diseases. Key products include the 31-valent pneumococcal conjugate vaccine VAX-31, which is currently in Phase 3 trials, and VAX-24, designed to cover more serotypes than existing infant PCVs.
Read more →PCVXVaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
Vaxcyte has initiated Phase 3 studies for its pneumococcal conjugate vaccine, VAX-31, targeting both adults and infants. The OPUS-2 trial is evaluating its coadministration with seasonal influenza vaccine, while the OPUS-3 trial will assess its efficacy in previously vaccinated adults. Topline data from these studies is expected in early 2027, supporting a planned BLA submission.
Read more →PCVXVaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte has initiated the OPUS Phase 3 trial for VAX-31, a vaccine aimed at preventing invasive pneumococcal disease and pneumonia in adults. The trial, which will enroll around 4,000 participants, is designed to compare VAX-31's safety, tolerability, and immunogenicity against existing vaccines. Topline results are expected in late 2026, supporting a future Biologics License Application.
Read more →PCVXVaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Vaxcyte reported positive final data from its VAX-24 infant Phase 2 study, confirming robust immune responses. The company is advancing its VAX-31 program into Phase 3, with an adult pivotal study expected to start in December 2025. Vaxcyte is also expanding its manufacturing capabilities in North Carolina, which aligns with its commercial strategy. The company maintains a strong financial position with significant cash reserves.
Read more →PCVXVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
Vaxcyte, Inc. has announced a new agreement with Thermo Fisher Scientific to establish fill-finish manufacturing for its pneumococcal conjugate vaccines in Greenville, North Carolina. This initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents an investment of up to $1 billion. The expansion aims to strengthen the company's supply chain and enhance its commercial readiness.
Read more →PCVXVaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Vaxcyte has advanced its VAX-31 infant Phase 2 dose-finding study to the final stage, with the first participants receiving the optimized dose. This 31-valent pneumococcal conjugate vaccine aims to enhance immune responses in infants against invasive pneumococcal disease. Topline data is expected by mid-2027, highlighting VAX-31's potential to cover a significant percentage of pneumococcal strains.
Read more →PCVX▼ -9.1%on this news
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
Vaxcyte reported its second quarter 2025 financial results, highlighting significant progress in the development of VAX-31, a potential best-in-class pneumococcal conjugate vaccine. Following FDA interactions, the company is finalizing its Phase 3 clinical program for adults, with a pivotal study set to begin in Q4 2025. Additionally, modifications to the pediatric Phase 2 study aim to enhance immune responses. Vaxcyte maintains a robust financial position to support its ongoing programs.
Read more →PCVX▲ +8.4%on this news
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
Vaxcyte reported positive topline safety and immunogenicity data from its Phase 2 study of VAX-24 in infants. The company has initiated the second stage of the VAX-31 infant Phase 2 study and plans to start a Phase 3 study for adults by mid-2025. With a strong financial position, Vaxcyte is well-equipped to advance its vaccine pipeline.
Read more →PCVXVaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
Vaxcyte, Inc. has appointed Dr. Olivier Brandicourt to its Board of Directors, enhancing its leadership team. Dr. Brandicourt, a former CEO of Sanofi, brings valuable experience in the biopharmaceutical sector, particularly in vaccine commercialization. His expertise is expected to support Vaxcyte's efforts in advancing its pneumococcal conjugate vaccine candidates toward global commercialization.
Read more →PCVX▼ -45.6%on this news· ran to -56% by day 3
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
Vaxcyte announced positive topline results from its Phase 2 dose-finding study of VAX-24, a 24-valent pneumococcal conjugate vaccine. The study showed that VAX-24 was well-tolerated and elicited substantial immune responses in healthy infants. The company plans to advance the mid dose of VAX-24 to a potential Phase 3 program, pending further data from the VAX-31 study.
Read more →PCVX▼ -45.6%on this news· ran to -56% by day 3shared move
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
Vaxcyte, Inc. will host a webcast and conference call on March 31, 2025, to present topline results from its VAX-24 Phase 2 study. This study evaluates the safety and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine, compared to Prevnar 20 in healthy infants. The results are anticipated to provide insights into the vaccine's effectiveness against invasive pneumococcal disease.
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update -- Completed Successful VAX-31 Phase 2 Adult Program Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non
Vaxcyte, Inc. announced its fourth quarter and full year financial results for 2024, highlighting significant progress in its vaccine programs. The successful completion of the VAX-31 Phase 2 Adult Program positions the company to launch a pivotal Phase 3 study by mid-2025. Vaxcyte's financial foundation has been bolstered by approximately $2.2 billion raised through follow-on equity offerings, facilitating further advancement of its clinical studies. Upcoming data from various ongoing studies are anticipated throughout 2025 and 2026, reflecting the company's commitment to combating bacterial diseases.
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Vaxcyte, Inc. will report its fourth quarter and full year 2024 financial results on February 25, 2025. A conference call will follow to discuss these results and provide a business update. The company is known for developing high-fidelity vaccines targeting bacterial diseases, with candidates like VAX-31 and VAX-24 in clinical trials.
Read more →PCVXVaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte, Inc. announced the advancement of its Phase 2 study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease in healthy infants. Following a review of Stage 1 safety and tolerability data, the company has begun the second stage of the study. Results from the primary immunization series are expected in mid-2026, with the potential for broader disease coverage compared to existing vaccines. This trial reflects Vaxcyte's commitment to enhancing protection against significant bacterial infections in vulnerable populations.
Read more →PCVXVaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025. The event will highlight Vaxcyte's work in developing advanced vaccines targeted at bacterial diseases, including their broad-spectrum candidates VAX-31 and VAX-24. The company aims to improve upon existing vaccines through innovative technologies and has a pipeline that includes several candidates for serious infections. A webcast of the event will be available for 30 days post-conference.
Read more →PCVXVaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte, Inc. has initiated a Phase 2 study for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV), in healthy infants. The study will assess the vaccine's safety, tolerability, and immunogenicity while comparing it to the existing Prevnar 20 vaccine. VAX-31 is designed to cover a significant majority of invasive pneumococcal disease and acute otitis media in children under five. Topline data from the primary immunization series are expected in mid-2026, with a booster dose evaluation to follow approximately nine months later.
Read more →PCVXVaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Vaxcyte, Inc. has announced significant regulatory advancements for its VAX-31 programs, receiving FDA clearance for the infant Investigational New Drug application and Breakthrough Therapy designation for adults. The VAX-31 vaccine, which targets invasive pneumococcal disease, is poised to enter Phase 2 trials in infants and Phase 3 pivotal studies in adults by mid-2025. The company aims to provide broad coverage against prevalent strains, addressing a crucial need for both pediatric and adult vaccinations. This follows positive results from prior clinical studies confirming the vaccine's promising efficacy and safety profile.
Read more →PCVXVaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1 2 Study of VAX-31, its 31-Valent Pneumococc
Vaxcyte, Inc. reported its third quarter 2024 financial results, highlighting favorable topline results from a Phase 1/2 study of its VAX-31 pneumococcal conjugate vaccine candidate. The study indicated strong safety and immunogenicity outcomes, leading to the decision to progress VAX-31 into a Phase 3 trial, expected to start by mid-2025. Significant financial backing, including $1.4 billion from a recent equity offering, positions the company to advance multiple clinical programs, including efforts for both adult and pediatric populations. Anticipated data milestones from these studies are set for 2025 and 2026.
Read more →PCVXVaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced its participation in the 2024 Cantor Global Healthcare Conference on September 18. The company is focused on developing high-fidelity vaccines to combat bacterial diseases, including their Phase 3-ready pneumococcal conjugate vaccine VAX-31 and VAX-24, which addresses multiple serotypes. The presentation will be accessible via live webcast, signifying the company's commitment to transparency and engagement with investors.
Read more →PCVXVaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte, a clinical-stage vaccine company, has successfully closed a public offering, raising around $1.5 billion by selling over 12 million shares at $103 each. This strategic financing empowers Vaxcyte to advance its pipeline of innovative vaccines aimed at tackling bacterial infections. The firm is focusing on high-fidelity vaccines, including candidates for pneumococcal diseases, Group A Strep, periodontal disease, and Shigella, enhancing its potential market impact.
Read more →PCVXVaxcyte Announces Pricing of $1.3 Billion Public Offering
Vaxcyte, a clinical-stage vaccine company, has announced the pricing of a public offering, seeking to raise approximately $1.3 billion by selling over 10 million shares of common stock and pre-funded warrants. The offering is set to close on September 6, 2024, pending standard closing conditions. The proceeds from this offering are intended to bolster Vaxcyte's ongoing efforts in developing vaccines targeting bacterial diseases, including advanced candidates for pneumococcal disease and Group A Strep infections.
Read more →PCVX▲ +36.4%on this newsshared move
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic
Vaxcyte has reported positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for adults aged 50 and older. The study showed robust opsonophagocytic immune responses for all 31 serotypes and a favorable safety profile that was similar to Prevnar 20. Based on these results, Vaxcyte plans to advance VAX-31 into a Phase 3 clinical program, with initial milestones expected by mid-2025. The vaccine is designed to enhance protection against invasive pneumococcal disease, which has critical implications for public health.
Read more →PCVX▲ +36.4%on this newsshared move
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
Vaxcyte, Inc. has announced a webcast and conference call scheduled for September 3, 2024, to discuss topline results from its Phase 1/2 study of the VAX-31 vaccine. This 31-valent pneumococcal conjugate vaccine is designed for adults aged 50 and older and aims to improve immunization against invasive pneumococcal disease. The company is focusing on broad-spectrum vaccines utilizing advanced synthetic techniques. VAX-31 builds on Vaxcyte's commitment to address significant health risks posed by bacterial infections.
Read more →PCVXVaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 1 2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Ad
Vaxcyte reported its financial results for the second quarter of 2024, highlighting a substantial cash reserve of $1.9 billion. The company is set to release topline data for the VAX-31 adult Phase 1/2 study later this year and aims to progress either VAX-24 or VAX-31 into Phase 3 trials. Despite an increase in net loss and R&D expenses compared to the previous year, Vaxcyte's advancements in its pneumococcal vaccine pipeline exemplify its commitment to improving public health through innovative vaccine solutions.
Read more →PCVXVaxcyte Appoints John Furey to Board of Directors
Vaxcyte, Inc. has appointed John Furey, an experienced biopharmaceutical executive, to its Board of Directors. Furey brings over 30 years of experience in vaccine commercialization and development, which Vaxcyte hopes to leverage as it advances its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31, toward late-stage clinical development. His expertise is expected to provide strategic insights in the company's mission to improve health outcomes related to bacterial diseases.
Read more →PCVXVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 1 2 Study Enrollment Completed Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarte
Vaxcyte reported its first quarter 2024 financial results, highlighting the successful completion of enrollments in its VAX-31 and VAX-24 studies. The company anticipates releasing topline safety, tolerability, and immunogenicity data for VAX-31 in Q3 2024, followed by VAX-24 data in early 2025. With a strong cash position bolstered by a recent public offering, Vaxcyte is planning to advance its pneumococcal conjugate vaccine programs into more advanced phases of clinical trials. However, the company reported a significant net loss of $95 million for the quarter, raising some concerns about ongoing operational costs.
Read more →PCVXVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. is set to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024. The company will deliver a fireside chat focusing on its ongoing efforts in vaccine innovation, particularly its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine. Vaxcyte is developing a range of vaccines to prevent or treat various bacterial infectious diseases, utilizing advanced synthetic techniques to ensure high-fidelity vaccine production. The conference will be accessible via a live webcast, with a replay available for 30 days post-event.
Read more →PCVXVaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Vaxcyte has completed enrollment for its Phase 2 study of VAX-24, a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease in infants. The study includes over 800 participants and evaluates safety, tolerability, and immunogenicity. Expected topline data from the primary immunization series are set to be announced by the end of Q1 2025, with additional data from a booster dose to follow by the end of the same year. VAX-24 is anticipated to provide broader coverage against pneumococcal disease compared to existing vaccines.
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected
Vaxcyte, Inc. has reported its financial results for Q4 and full year 2023, highlighting significant advancements in its pneumococcal conjugate vaccine (PCV) franchise. Enrollment for the VAX-31 Adult Program Phase 1/2 study is now complete, with topline safety data expected by Q3 2024. Progress was also noted in the VAX-24 program, which is now deemed Phase 3-ready after a successful End-of-Phase 2 meeting with the FDA. The company is strategically expanding its production capabilities and has a robust cash position of $1.2 billion, which will support upcoming clinical trials and operational growth.
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Vaxcyte, Inc. (Nasdaq: PCVX) announced it will report its fourth quarter and full year 2023 financial results on February 27, 2024. The company, known for developing high-fidelity vaccines, will hold a conference call to discuss these results and provide a business update. Vaxcyte's lead candidate, VAX-24, is in Phase 3 and aims to enhance prevention of invasive pneumococcal disease. The firm is leveraging advanced techniques for vaccine development, including novel protein synthesis methods.
Read more →PCVXVaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte, Inc. has successfully closed a public offering of 12,695,312 shares of common stock, raising approximately $862.5 million. The offering included a full exercise of the underwriters’ option to purchase additional shares, highlighting strong investor interest. Vaxcyte is advancing its development of high-fidelity vaccines aimed at preventing bacterial diseases, with its lead candidate, VAX-24, being Phase 3-ready. The company leverages modern synthetic techniques to innovate vaccine production processes.
Read more →PCVX▲ +5.8%on this newsshared move
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Vaxcyte, Inc. (Nasdaq: PCVX) will present at the Guggenheim Healthcare Talks during the 6th Annual Biotechnology Conference on February 8, 2024. The company is known for developing high-fidelity vaccines targeting bacterial diseases, including its lead candidate VAX-24. The presentation offers Vaxcyte an opportunity to showcase its advancements in vaccine innovation and synthetic production techniques. A live webcast of the event will be accessible through the company's website, with a replay available for 30 days post-conference.
Read more →PCVX▲ +6%on this newsshared move
Vaxcyte Announces Pricing of $750 Million Public Offering
Vaxcyte, Inc. announced the pricing of a public offering of common stock and pre-funded warrants, aimed at raising approximately $750 million. The offering involves the sale of 10,937,500 shares of common stock at a price of $64.00 each, alongside pre-funded warrants for additional shares. The offering is scheduled to close on February 2, 2024, pending customary closing conditions. Vaxcyte's innovative vaccine development approach, particularly in its lead candidate VAX-24, aims to advance the field of bacterial disease prevention.
Read more →PCVX▲ +6.5%on this news· ran to +17% by day 3shared move
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Vaxcyte, Inc. has announced the completion of enrollment for its Phase 1/2 study of VAX-31, a pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease in adults aged 50 and older. The trial, involving 1,015 participants, is designed to evaluate the safety, tolerability, and immunogenicity of VAX-31 compared to a current vaccine standard, Prevnar 20. Results are expected in the third quarter of 2024, marking a significant step for Vaxcyte's plans to expand its vaccine portfolio aimed at addressing public health needs.
Read more →PCVXVaxcyte Appoints Whitney Jones as Chief People Officer
Vaxcyte, Inc. announced the appointment of Whitney Jones as Chief People Officer, tasked with enhancing the company's human resources strategy. With over 20 years of experience, Jones aims to foster a strong company culture while supporting organizational growth strategies. As Vaxcyte scales its operations to advance its pipeline of vaccines, including its lead programs VAX-24 and VAX-31, Jones' leadership will be pivotal in maintaining employee engagement and talent acquisition.
Read more →PCVXVaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
Vaxcyte, Inc. announced significant updates regarding its pneumococcal conjugate vaccine franchise, including progress in the VAX-31 program and plans for the VAX-24 Phase 3 pivotal study. The company commenced dosing participants in the Phase 2 study of VAX-31 and received positive input from the FDA regarding the licensure requirements for VAX-24. Upcoming data releases are anticipated in 2024 and 2025, which Vaxcyte believes will support the development of a best-in-class vaccine against invasive pneumococcal disease. The strategic advancements suggest an optimistic outlook for the company’s pipeline.
Read more →PCVXVaxcyte Appoints Jacks Lee to Board of Directors
Vaxcyte, Inc. has appointed Jacks Lee to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical sector. Lee's expertise in manufacturing and supply chain operations is expected to provide valuable strategic insights as Vaxcyte progresses with its pipeline, including its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. This appointment comes as Vaxcyte focuses on its mission to develop vaccines addressing bacterial diseases, utilizing modern synthetic techniques that enhance vaccine efficacy.
Read more →PCVXVaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Vaxcyte, Inc. has exercised an option to enter into a manufacturing rights agreement with Sutro Biopharma, securing exclusive rights to develop and manufacture cell-free extract for its pneumococcal conjugate vaccines, including VAX-24 and VAX-31. This move is part of Vaxcyte's broader strategy to control critical aspects of vaccine development as VAX-24 progresses to Phase 3 trials. The agreement involves significant financial commitments, including an initial payment of $50 million and potential milestone payments totaling up to $60 million based on regulatory milestones.
Read more →PCVX▼ -5.1%on this news
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Vaxcyte has begun dosing participants in a Phase 1/2 clinical study for VAX-31, a 31-valent pneumococcal conjugate vaccine intended to prevent invasive pneumococcal disease in adults. The study, which aims to enroll around 1,000 adults aged 50 and older, will evaluate the vaccine's safety, tolerability, and immunogenicity compared to Prevnar 20. Results from the study are anticipated in the second half of 2024, bringing potential advancements for broader pneumococcal disease protection.
Read more →PCVXVaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update -- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 -- -- Received FDA Cle
Vaxcyte, Inc. reported its financial results for Q3 2023, highlighting a successful End-of-Phase 2 meeting with the FDA for its VAX-24 vaccine, which is slated for Phase 3 trials expected to produce topline data in 2025. Additionally, the company secured FDA clearance for its VAX-31 vaccine, initiating a Phase 1/2 study. Vaxcyte maintains a robust cash position of $1.4 billion, but reports a net loss of $92.7 million and increased R&D expenditures, signaling the intensifying costs associated with its clinical development efforts. The company also announced an expanded collaboration with Lonza for commercial manufacturing of its vaccine candidates.
Read more →PCVXVaxcyte to Present at Upcoming Investor Conferences
Vaxcyte, Inc. is scheduled to participate in several upcoming investor conferences, including the Guggenheim 5th Annual Inflammation & Immunology Conference, Jefferies London Healthcare Conference, and Evercore ISI 6th Annual HealthCONx Conference. The company will host fireside chats and one-on-one meetings to discuss its innovative approach to vaccine development, particularly targeting bacterial diseases. Vaxcyte's lead candidate, VAX-24, a pneumococcal conjugate vaccine, is progressing to late-stage development, reflecting the company's commitment to enhancing vaccine efficacy through modern technologies.
Read more →PCVXVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Vaxcyte, Inc. announced that the FDA has cleared its Investigational New Drug application for VAX-31, a 31-valent pneumococcal conjugate vaccine. The company plans to initiate a Phase 1/2 clinical study in healthy adults aged 50 and older within the fourth quarter of this year. Results regarding safety, tolerability, and immunogenicity are expected in the second half of 2024. VAX-31 is designed to cover around 95% of the serotypes currently causing invasive pneumococcal disease in the adult population in the U.S.
Read more →PCVXVaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
Vaxcyte, Inc. has expanded its collaboration with Lonza to support the global commercialization of its pneumococcal vaccine candidates, VAX-24 and VAX-31. A new manufacturing agreement designates a custom-built suite at Lonza's facility in Visp, Switzerland, aimed at meeting the production needs for both adult and pediatric populations. This collaboration builds on Vaxcyte's ongoing clinical development, with VAX-24 progressing to late-stage trials after positive outcomes in earlier phases. The partnership aims to increase production capabilities and boost the availability of vaccines that target invasive pneumococcal disease.
Read more →PCVXVaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Vaxcyte, Inc. will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 26, 2023. The company specializes in developing innovative vaccines against bacterial diseases, including its lead candidate, the VAX-24 pneumococcal conjugate vaccine. Their technology features modern synthetic techniques aimed at improving vaccine production. A live webcast will be available on their website, with replays accessible for 30 days after the event.
Read more →PCVXVaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update -- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Im
Vaxcyte, Inc. reported strong financial results for Q2 2023, advancing its VAX-24 vaccine candidate towards broader pneumococcal disease prevention. The company announced that the Phase 2 Infant Study has progressed to its second stage with new participants enrolled. Significant financial backing of $1.4 billion positions Vaxcyte well for upcoming regulatory processes as they prepare for Phase 3 trials and further developments in their vaccine pipeline. Notably, they also completed a $575 million follow-on financing earlier in the year.
Read more →PCVXVaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte, Inc. has announced the advancement of its VAX-24 vaccine candidate into the second stage of an ongoing Phase 2 study, following approval from the independent Data Safety Monitoring Board based on initial safety assessments. This study focuses on the vaccine's safety, tolerability, and immunogenicity in healthy infants, comparing VAX-24 with the current standard PCV, Prevnar 20®. The company anticipates sharing topline data from the primary immunization series by 2025, potentially reinforcing the need for broader-spectrum pneumococcal vaccines.
Read more →PCVXVaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte, Inc. will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2023. The company's focus is on creating innovative vaccines to combat bacterial diseases, including its lead candidate VAX-24. Vaxcyte utilizes advanced synthetic techniques for vaccine development, with a diverse pipeline targeting various bacterial infections. The event will feature a live webcast and a replay available for about 30 days post-conference.
Read more →PCVXVaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update -- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) a
Vaxcyte, Inc. reported strong financial results for Q1 2023, highlighted by positive data from the Phase 2 study of its VAX-24 vaccine candidate in adults aged 65 and older. The vaccine demonstrated robust immune responses across all studied serotypes and is advancing towards Phase 3 trials. Vaxcyte's financial position was bolstered by a recent follow-on equity offering that raised approximately $575 million. Additionally, the company received Breakthrough Therapy designation from the FDA, enhancing its development support for VAX-24, which aims to prevent invasive pneumococcal disease.
Read more →PCVX▲ +5.2%on this newsshared move
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
SAN CARLOS, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will partici
Read more →PCVXVaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously anno
Read more →PCVXVaxcyte Announces Pricing of $500 Million Public Offering
SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten pub
Read more →PCVX▲ +16%on this newsshared move
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies VAX-
Vaxcyte reported encouraging results from its Phase 2 study of VAX-24, a 24-valent pneumococcal conjugate vaccine, which showed strong immune responses in adults aged 65 and older. The vaccine met non-inferiority and superiority criteria compared to the existing PCV20. Full six-month safety data indicated VAX-24's safety and tolerability were similar to PCV20. The company plans to advance VAX-24 into a pivotal Phase 3 study, with topline data anticipated in 2025.
Read more →PCVX▲ +16%on this newsshared move
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and confere
Read more →PCVXVaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 -- -- The Nine Incremental Serotypes in VAX-24 Cover an Additional 20-25 Percent of Strains Causing Invasive Pneumococcal Disease Over the Current Standar
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -- Company Received U.S. Food and Drug Administration (FDA) Clearance of VAX-24 Infant Investigational New Drug (IND) Appli
Vaxcyte has announced its financial results for Q4 2022 and the full year, highlighting significant advancements in its vaccine pipeline. The company received FDA clearance for the VAX-24 IND application aimed at preventing invasive pneumococcal disease in infants and expects to initiate a Phase 2 study soon. Positive topline results from previous Phase 1/2 studies suggest a potentially leading position for VAX-24, and the company is progressing with its broader vaccine initiatives, including the VAX-31 candidate. With approximately $805 million raised in 2022, Vaxcyte is well-positioned for continued growth and development.
Read more →PCVXVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2 Proof-of-Concept Study Results in Adults, FDA Supported Initiation of Pediatric P
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial resul
Read more →PCVXVaxcyte to Present at the SVB Securities Global Biopharma Conference
SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will partic
Read more →PCVXVaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenic
Read more →PCVXVaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update -- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Cand
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update -- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pne
Read more →PCVX▲ +5.4%on this news
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously annou
Read more →PCVX▲ +17%on this newsshared move
Vaxcyte Announces Pricing of $600 Million Public Offering
SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten publ
Read more →PCVX▲ +60.3%on this news· ran to +100% by day 3shared move
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 In the Study, VAX-24 Demonstrated a Safety and Toler
Read more →PCVX▲ +60.3%on this news· ran to +100% by day 3shared move
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conferen
Read more →PCVXVaxcyte Expands Executive Leadership Team with Key Appointments
-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer as the Company Prepares to Enter Next Phase of Growth -- SAN CARLOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-sta
Read more →PCVXVaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or Nov
Read more →PCVXVaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update -- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicit
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update -- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Result
Read more →PCVXVaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly into Infants -- -- VAX-24 is 24-Valent Pneumococcal Conjugate Vaccine Designed
Read more →PCVXVaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
-- Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 -- -- Vaxcyte Also Dosed First Participants in Separate VAX-24 Phase 2 Clinical Study in Adults 65 Years and Older, With Topline Data Ex
Read more →PCVX▼ -11.8%on this news
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update -- Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update -- Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Diseas
Read more →PCVXVaxcyte to Participate in Upcoming Investor Conferences in May
SAN CARLOS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will partici
Read more →PCVXVaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will parti
Read more →PCVX▲ +7.1%on this newsshared move
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
-- Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned -- -- Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update -- First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disea
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update -- First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults -- -- VAX-24 Phase 1/2 Study To
Read more →PCVXVaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
-- Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spect
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the four
Read more →PCVXVaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th A
Read more →PCVX▼ -9.5%on this news· ran to -20% by day 3
Vaxcyte Announces Pricing of $100 Million Public Offering
SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the pricing of an underwritten public offering of
Read more →PCVX▼ -6.8%on this news· ran to -23% by day 3shared move
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offer
Read more →PCVXVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
-- Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection -- SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE)
Read more →PCVXVaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update -- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxic
Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update -- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study -- FOSTER CITY, Calif., November 10, 2021 - V
Read more →PCVX▲ +5.7%on this news
Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases wo
Read more →PCVXVaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases w
Read more →PCVXVaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference
FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases w
Read more →PCVXVaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors
FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases w
Read more →PCVXVaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update
Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update FOSTER CITY, Calif., August 11, 2021 - Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to preven
Read more →PCVXVaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections
-- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones -- -- Vaxcyte Plans to Initiate IND-Enabling Studies for VAX-A1 in Second Half of 2021 -- FOSTER CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte,
Read more →PCVXVaxcyte to Present at the Jefferies Virtual Healthcare Conference
FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases wor
Read more →PCVXVaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update
Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update FOSTER CITY, Calif., May 11, 2021 - Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or
Read more →PCVXVaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease
FOSTER CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases wor
Read more →PCVXVaxcyte to Present at BofA Securities 2021 Health Care Conference
FOSTER CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases wor
Read more →PCVXVaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference
FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases w
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update FOSTER CITY, Calif., March 29, 2021 - Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines desig
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases w
Read more →PCVXVaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections
FOSTER CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today
Read more →PCVXVaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer
FOSTER CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectiou
Read more →PCVXVaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference
FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectiou
Read more →PCVXVaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update Foster City, Calif.
Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update Foster City, Calif., November 12, 2020 - Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines des
Read more →PCVXVaxcyte to Present at Jefferies Virtual London Healthcare Conference
FOSTER CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectiou
Read more →PCVXVaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference
FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectio
Read more →PCVXVaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update Foster City, Calif.
Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update Foster City, Calif., August 12, 2020 - Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines desi
Read more →PCVXVaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares FOSTER CITY, Calif., June 16, 2020 Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superio
Read more →PCVXVaxcyte Announces Pricing of Upsized Initial Public Offering
FOSTER CITY, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today
Read more →PCVXVaxcyte Appoints Halley E. Gilbert to Board of Directors
FOSTER CITY, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectiou
Read more →Competitive Position
How PCVX ranks across every disease it competes inCompetitive Position is a premium feature
See how PCVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial